Natural Product (NP) Details
General Information of the NP (ID: NP6854) | |||||
---|---|---|---|---|---|
Name |
Vitamin K2
|
||||
Synonyms |
menatetrenone; vitamin K2; Menaquinone-4; 863-61-6; Menaquinone 4; Kefton-2; Vitamin MK 4; Kaytwo; Menaquinone K4; Menatetrenona; Menatetrenonum; 11032-49-8; 2-Methyl-3-trans-tetraprenyl-1,4-naphthoquinone; MK-4; UNII-27Y876D139; 2-Methyl-3-geranylgeranyl-1,4-naphthoquinone; C31H40O2; MLS000028742; 6041-00-5; CHEBI:78277; MFCD00079646; 2-Methyl-3-((2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl)naphthalene-1,4-dione; 2-methyl-3-[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl]naphthalene-1,4-dione; MK4; SMR000058955; 27Y876D139; 1,4-Naphthalenedione, 2-methyl-3-(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl)-; 2-Methyl-3-(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl)-1,4-naphthoquinone; DSSTox_CID_28895; Vitamin K2(sub 20); Menatetrenone [INN:JAN]; Menatetrenonum [INN-Latin]; K2(sub 20); Menatetrenona [INN-Spanish]; Glakay; E3100; menaquinone(4); NCGC00183125-01; 2-methyl-3-((2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl)naphthalene-1,4-dione; Vitamin K2 (TN); Opera_ID_148; 2-Methyl-3-tetraprenyl-1,4-naphthoquinone; 2-Methyl-3-(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl)-1,4-naphthochinon; DSSTox_RID_80857; DSSTox_RID_83163; Menatetrenone (JP17/INN); DSSTox_GSID_45406; DSSTox_GSID_48969; 1,4-Naphthalenedione, 2-Methyl-3-(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl)-, (E,E,E)-; MENAQUINONE;VITAMIN K2; SCHEMBL434553; SCHEMBL571912; Menaquinone 4; ; ; Menatetrenone; Vitamin K2 (MK-4) solution; CHEMBL259223; MQ-4; DTXSID6048969; HMS2230J06; Ea-0167; AMY22672; HY-B2156; ZINC3874199; Tox21_110567; Tox21_113413; BDBM50423776; s5082; AKOS025311021; Menaquinone (K2), analytical standard; CCG-269176; DB12148; 2-Methyl-3-(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl)-1,4-naphthalenedione; NCGC00181325-01; NCGC00181325-03; 1,4-Naphthalenedione, 2-methyl-3-((2E,6E,10E)3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl)-; AS-17910; AS-56161; CAS-863-61-6; K541; CS-0020307; V2671; A17083; D00100; E-0167; 863V616; Q192354; 2-Methyl-3-(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetrenyl)-1,4-naphthoquinone; 1,4-Naphthalenedione, 2-methyl-3-[(2E,6E,10E)-3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl]-; 2-methyl-3-[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl]-1,4-naphthoquinone; Vitamin K2 (MK-4) solution, 100 mug/mL in acetonitrile, ampule of 1 mL, certified reference material
Click to Show/Hide
|
||||
Species Origin | Glycine max ... | Click to Show/Hide | |||
Glycine max | |||||
Disease | Bladder cancer [ICD-11: 2C94] | Investigative | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C31H40O2
|
||||
PubChem CID | |||||
Canonical SMILES |
CC1=C(C(=O)C2=CC=CC=C2C1=O)CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C
|
||||
InChI |
1S/C31H40O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,12,14,16,18-20H,9-11,13,15,17,21H2,1-6H3/b23-14+,24-16+,25-20+
|
||||
InChIKey |
DKHGMERMDICWDU-GHDNBGIDSA-N
|
||||
CAS Number |
CAS 863-61-6
|
||||
ChEBI ID | |||||
Herb ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Sorafenib | Renal cell carcinoma | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
Hep 3B2.1-7 | CVCL_0326 | Childhood hepatocellular carcinoma | Homo sapiens | |||
Huh-7 | CVCL_0336 | Adult hepatocellular carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Combined treatment with sorafenib and vitamin K2 can work synergistically to inhibit the growth of hepatocellular carcinoma cells. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Trypanosoma Cruzipain (Trypano CYSP) | Molecule Info | [3] |